These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 3029598)

  • 1. Cell fusion in viral diseases.
    Chany C; Chany-Fournier F; Robain O
    Nature; 1987 Mar 19-25; 326(6110):250. PubMed ID: 3029598
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of concanavalin A on viral infectivity, maturation and cytopathogenicity in vesicular stomatitis virus-infected cells.
    Takehara M
    Kobe J Med Sci; 1979 Dec; 25(4):205-16. PubMed ID: 230383
    [No Abstract]   [Full Text] [Related]  

  • 3. Polarity and fusion of JAR choriocarcinoma cells as assessed by enveloped viral glycoproteins.
    Olli RA; Rajaniemi HJ; Rydbeck R; Metsikkö K
    Exp Cell Res; 1993 Jun; 206(2):276-82. PubMed ID: 8388801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection of the central nervous system produced by R1 vesicular stomatitis virus.
    Greenstein JI; Baron-Van Evercooren AG; Lazzarini RA; McFarland HF
    Lab Invest; 1981 Jun; 44(6):487-95. PubMed ID: 6262567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous response of antiserum-treated cell clones from a persistently infected DBT cell line to mouse hepatitis virus.
    Makino S; Taguchi F; Fujiwara K; Hayami M
    Jpn J Exp Med; 1982 Dec; 52(6):297-302. PubMed ID: 6302351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal molecular and cellular requirements for elicitation of secondary anti-vesicular stomatitis virus cytotoxic T lymphocytes.
    Hale AH; Ruebush MJ
    J Immunol; 1980 Oct; 125(4):1569-77. PubMed ID: 6251135
    [No Abstract]   [Full Text] [Related]  

  • 7. Requirement of carbohydrates for cell fusion induced by vesicular stomatitis virus.
    Takehara M
    Microbiol Immunol; 1981; 25(4):377-85. PubMed ID: 6265740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular stomatitis antigens recognized by cytotoxic cells: analysis with defective interfering particles and reconstituted membrane vesicles.
    Ciavarra RP; Kang CY; Forman J
    J Immunol; 1980 Jul; 125(1):336-43. PubMed ID: 6247397
    [No Abstract]   [Full Text] [Related]  

  • 9. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
    Fredericksen BL; Whitt MA
    Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
    Kahn JS; Schnell MJ; Buonocore L; Rose JK
    Virology; 1999 Feb; 254(1):81-91. PubMed ID: 9927576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic viral neuropathies: models for study and food for thought.
    Koprowski H
    Int Arch Allergy Appl Immunol; 1969; 36():Suppl:158-81. PubMed ID: 4313663
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
    Levin Perlman S; Jordan M; Brossmer R; Greengard O; Moscona A
    Virology; 1999 Dec; 265(1):57-65. PubMed ID: 10603317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activities of silver sulfadiazine in ocular infection.
    Tokumaru T; Shimizu Y; Fox CL
    Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):151-8. PubMed ID: 4368031
    [No Abstract]   [Full Text] [Related]  

  • 14. Morphological and biochemical characterization of vesicular stomatitis virus with low infectivity released from interferon treated cells.
    Maheshwari RK; Friedman RM
    Uttar Pradesh State Dent J; 1980 Jul; 11(3):95-110. PubMed ID: 6159713
    [No Abstract]   [Full Text] [Related]  

  • 15. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.
    Ah-Tye C; Schwartz S; Huberman K; Carlin E; Moscona A
    Microb Pathog; 1999 Nov; 27(5):329-36. PubMed ID: 10545258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.
    Kuate S; Stahl-Hennig C; Stoiber H; Nchinda G; Floto A; Franz M; Sauermann U; Bredl S; Deml L; Ignatius R; Norley S; Racz P; Tenner-Racz K; Steinman RM; Wagner R; Uberla K
    Virology; 2006 Jul; 351(1):133-44. PubMed ID: 16616946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of vesicular stomatitis virus through inhibition of membrane fusion by chemical modification of the viral glycoprotein.
    Stauffer F; De Miranda J; Schechter MC; Carneiro FA; Salgado LT; Machado GF; Da Poian AT
    Antiviral Res; 2007 Jan; 73(1):31-9. PubMed ID: 16934341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus.
    Rosenthal KL; Zinkernagel RM
    J Immunol; 1980 May; 124(5):2301-8. PubMed ID: 6154097
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathogenesis of vesicular stomatitis virus infection in the infant hamster and mouse.
    Bruno-Lobo M; Peralta PH; Bruno-Lobo GG; de Paola D
    An Microbiol (Rio J); 1968; 15():53-68. PubMed ID: 4316894
    [No Abstract]   [Full Text] [Related]  

  • 20. Elicitation and specificity of anti-vesicular stomatitis virus-specific cytotoxic T lymphocytes.
    Ruebush MJ; Hale AH; Lefrancois L; Harris DT; Burgess DE
    J Immunol; 1981 May; 126(5):2053-9. PubMed ID: 6260862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.